

North America Interventional Cardiology Market Analysis 2025–2033 | Reaching \$11.98 Billion by 2033 DataM Intelligence

North America's Interventional Cardiology Market is set to grow from USD 7.04B in 2024 to USD 11.98B by 2033, driven by rising Heart Disease and Tech

AUSTIN, TX, UNITED STATES, June 13, 2025 /EINPresswire.com/ -- North America Interventional Cardiology Market: 2025 Outlook and Developments

In 2025, the [North American Interventional Cardiology Market Size](#) was valued at USD 7.04 Billion and is expected to reach around USD 11.98 Billion by 2033, reflecting steady growth With a CAGR 6.2% at a strong compound annual rate over the forecast period 2025-2033

“

The U.S. Interventional Cardiology Market is a major contributor to North America's \$7.04B valuation in 2024, driven by rising heart disease rates and demand for minimally invasive procedures.”

DataM Intelligence


To Download Sample Report:

<https://datamintelligence.com/download-sample/north-america-interventional-cardiology-market>

Latest Industry Developments

In December 2024, Terumo Interventional Systems (TIS) announced the U.S. commercial launch of its R2P NaviCross peripheral support catheter, marking another step in the expansion of its radial-to-peripheral (R2P) product line.

In October 2024, Medtronic plc received FDA approval for its Affera Mapping and Ablation System, including the Sphere-9 Catheter, designed for treating persistent atrial fibrillation (AFib) and performing RF ablation of CTI-dependent atrial flutter.



In July 2024, Teleflex gained FDA approval for its Ringer Perfusion Balloon Catheter (PBC) currently the only approved perfusion balloon available for Percutaneous Transluminal Coronary Angioplasty (PTCA) procedures in the U.S.

In March 2024, Boston Scientific received FDA clearance for its Agent Drug-Coated Balloon (DCB), developed to treat coronary in-stent restenosis (ISR) in patients suffering from coronary artery disease.

Regional Outlook

United States

In the U.S., interventional cardiology is undergoing rapid digitization. Robotic-assisted procedures, artificial intelligence in diagnostics, and remote surgical support tools are shaping the future of care. Key urban centers, such as New York, Boston, and San Francisco, are witnessing accelerated adoption of advanced tools like drug-eluting stents, intravascular ultrasound (IVUS), and optical coherence tomography (OCT).

Canada

Canada, though smaller in scale, shows remarkable progress. Government-driven initiatives promoting innovation in healthcare technology have accelerated the growth of regional R&D hubs. Additionally, cross-border collaborations with the U.S.-based healthcare firms are leading to faster adoption of novel cardiac care products in Canadian hospitals.

Key Companies Driving Innovation

Several major companies are shaping the future of interventional cardiology in North America:

Medtronic

Boston Scientific Corporation

Abbott.

Canon Medical Systems Corporation

Teleflex Incorporated.

B. Braun SE

Johnson & Johnson Services, Inc.

Koninklijke Philips N.V.

Cook Medical

Market Segmentation

By Modality: Stents, Drug-Eluting Stents, Bare-Metal Stents, Bio-Absorbable Stents, Catheters, Angiographic Catheters, Guiding Catheters, Balloon Catheters, Intravascular Ultrasound (IVUS) Catheters, Aspiration Catheters, Others, Balloons, Guidewires, Imaging Systems, Intravascular Ultrasound System (IUVS), Optical Coherence Tomography (OCT) Systems, Fractional Flow Reserve (FFR) Systems, Others, Thrombectomy Systems, Atherectomy Systems, Closure Devices, Chronic Total Occlusion Systems (CTO), Others

By End-User: Hospitals, CATH Labs, Ambulatory Surgical Centers, Others

Latest News of USA

In April 2025, a major milestone was achieved when a leading university hospital in Texas performed its first AI-assisted percutaneous coronary intervention (PCI) using a fully integrated robotic system. The system enabled precise stent placement with real-time feedback and predictive modeling, drastically reducing procedural errors.

Meanwhile, the FDA has recently approved a biodegradable stent system developed by a Silicon Valley med-tech firm. This device is designed to dissolve naturally in the body within 18 months, eliminating long-term complications often associated with metal stents. This innovation has caught the attention of cardiologists nationwide who seek to reduce repeat procedures and side effects.

Also making waves is the CardioTrack Initiative, launched in partnership between the American College of Cardiology and several top-tier device manufacturers. The program aims to install AI-enabled monitoring kiosks in rural communities to identify early signs of cardiac distress.

Latest News of Japan

Although the main focus is North America, Japan's latest developments in interventional cardiology are creating ripple effects globally, including in North America through research collaboration and technology transfer.

In March 2025, Tokyo-based medical tech company Hirota Meditech unveiled a new bioresorbable valve replacement system, suitable for patients who are ineligible for open-heart surgery. The valve, designed for catheter-based implantation, is already gaining attention from global cardiac communities.

Additionally, Japan's National Center for Global Health and Medicine announced successful clinical trials using a hybrid imaging system that combines intravascular ultrasound and AI-based blood flow analytics. This system has drastically improved the identification of vulnerable plaques a significant breakthrough for preventing heart attacks.

Japanese companies are also deepening ties with North American counterparts. For instance, a collaboration between Osaka University and a U.S. biotech firm is underway to co-develop smart microcatheters capable of delivering drugs precisely within coronary arteries.

Conclusion

The North American interventional cardiology market is in the midst of a revolution. Fueled by aging demographics, an increase in lifestyle diseases, and unparalleled advancements in technology, the region is setting new standards in cardiac care. From robotic procedures and biodegradable implants in the U.S. to precision imaging tools from Japan, the global ecosystem is closely interconnected.

As the market grows, so too does the promise of better, safer, and more efficient heart treatments making the future of cardiology both high-tech and highly human-focused.

Here are the Latest Experts Related Reports By DataM Intelligence

[US Interventional Cardiology Market Size 2025-2033](#)

[Interventional Cardiology Market Size](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/821812126>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.